Melexis NV (MELE)
Euronext Brussels · Belgium · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 55.85 |
|---|---|
| 52-week range | 48.60 – 86.70 |
| Return, 1 month / 3 months | −17.0% / −21.2% |
| Return, 1 year / 3 years | −5.2% / −13.7% |
| Trend | Below its 200-day average |
| RSI (14) | 29 |
| Volatility (1 year) | 40.2% |
| Worst drawdown (1 year) | -33.6% |
| Average daily value traded | 2.67M EUR |
| Dividend yield | 6.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Melexis is a Belgian semiconductor company that designs and makes integrated circuits and sensors, with a strong focus on the automotive market. Its products include position sensors, temperature sensors, magnetic sensors and interface chips used in vehicles and in some industrial and consumer applications. The company is based in Tessenderlo, Belgium, and supplies carmakers and automotive component suppliers around the world with the electronic parts that go into modern vehicles.
On this site Melexis NV appears as a stock on the Euronext Brussels (Belgium), code MELE, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Melexis NV (MELE) trades on the Euronext Brussels in Belgium. It last closed at EUR 55.85 on 23 October 2026.
Its price-based Market X-Ray is 45 out of 100 (a weak price profile), ranking 75 of 111 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 5.2% and over the last three months it fell 21.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Brussels
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 36 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -13.8% | ||
| From 52-week high | -34.9% | ||
| Momentum | 36 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -21.2% | ||
| 6-month return | -14.3% | ||
| 12-month return, skipping the last month | 14.1% | ||
| Stability (higher is calmer) | 30 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 40.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -33.6% | ||
| Liquidity | 83 · Strong | Trades actively. | |
| Average daily value traded | 2.67M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 68 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 6.6% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −3.3% |
|---|---|
| 1 month | −17.0% |
| 3 months | −21.2% |
| 6 months | −14.3% |
| 1 year | −5.2% |
| 3 years | −13.7% |
| 5 years | −25.7% |
Signals
| 50-day / 200-day average | 63.80 / 64.77 |
|---|---|
| Golden / death cross (60 days) | Death, 3 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.91 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 13 Oct 2026 | EUR 1.3000 |
| 19 May 2026 | EUR 2.4000 |
| 14 Oct 2025 | EUR 1.3000 |
| 20 May 2025 | EUR 2.4000 |
| 15 Oct 2024 | EUR 1.3000 |
| 15 May 2024 | EUR 2.4000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Brussels; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.